Chengzhi Shareholding vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chengzhi Shareholding Co Ltd (000990.CS)

Q3 202619 Jul – 12 Aug 2026

▲3▼1

Chengzhi profit surges 14-fold, but goodwill risk looms

First-half profit surges over 14-fold Chengzhi's first-half 2026 net profit hit 290 million yuan, up 1,416% from a year earlier, with revenue up 2.77%. The clean energy and new chemical materials businesses worked together. This confirms the turnaround is real, supporting the stock price.
This is the actual reported result, the core new fact that validates the earlier profit forecast.
Earnings preview pointed to huge profit jump In mid-July, Chengzhi said first-half profit would rise 1,259% to 1,573% year on year, part of a broad Shenzhen-listed chemical sector recovery. The forecast set expectations high and helped lift the shares before the actual report.
This was the first signal of the profit surge and explains the positive momentum leading into the report.
6.6 billion yuan goodwill overhang Chengzhi carries 6.69 billion yuan of goodwill, about 24% of total assets, mostly from Nanjing Chengzhi Clean Energy. Investors worry a future writedown could hit earnings. The company also warned second-quarter profit may be far below the first quarter.
This is the main risk that could push the stock down and balances the positive earnings news.
Bonus share transfer and dividend registration Chengzhi registered a plan to transfer 4 bonus shares for every 10 held, the highest ratio among 15 companies that day. While this does not change the company's value, it often attracts short-term buying interest.
This corporate action can affect near-term demand for the shares and is a new event this period.

July 202619 Jul – 12 Aug 2026

▲3▼1

Chengzhi profit surges 14-fold, but goodwill risk looms

First-half profit surges over 14-fold Chengzhi's first-half 2026 net profit hit 290 million yuan, up 1,416% from a year earlier, with revenue up 2.77%. The clean energy and new chemical materials businesses worked together. This confirms the turnaround is real, supporting the stock price.
This is the actual reported result, the core new fact that validates the earlier profit forecast.
Earnings preview pointed to huge profit jump In mid-July, Chengzhi said first-half profit would rise 1,259% to 1,573% year on year, part of a broad Shenzhen-listed chemical sector recovery. The forecast set expectations high and helped lift the shares before the actual report.
This was the first signal of the profit surge and explains the positive momentum leading into the report.
6.6 billion yuan goodwill overhang Chengzhi carries 6.69 billion yuan of goodwill, about 24% of total assets, mostly from Nanjing Chengzhi Clean Energy. Investors worry a future writedown could hit earnings. The company also warned second-quarter profit may be far below the first quarter.
This is the main risk that could push the stock down and balances the positive earnings news.
Bonus share transfer and dividend registration Chengzhi registered a plan to transfer 4 bonus shares for every 10 held, the highest ratio among 15 companies that day. While this does not change the company's value, it often attracts short-term buying interest.
This corporate action can affect near-term demand for the shares and is a new event this period.

Latest19 Jul – 12 Aug 2026

▲3▼1

Chengzhi profit surges 14-fold, but goodwill risk looms

First-half profit surges over 14-fold Chengzhi's first-half 2026 net profit hit 290 million yuan, up 1,416% from a year earlier, with revenue up 2.77%. The clean energy and new chemical materials businesses worked together. This confirms the turnaround is real, supporting the stock price.
This is the actual reported result, the core new fact that validates the earlier profit forecast.
Earnings preview pointed to huge profit jump In mid-July, Chengzhi said first-half profit would rise 1,259% to 1,573% year on year, part of a broad Shenzhen-listed chemical sector recovery. The forecast set expectations high and helped lift the shares before the actual report.
This was the first signal of the profit surge and explains the positive momentum leading into the report.
6.6 billion yuan goodwill overhang Chengzhi carries 6.69 billion yuan of goodwill, about 24% of total assets, mostly from Nanjing Chengzhi Clean Energy. Investors worry a future writedown could hit earnings. The company also warned second-quarter profit may be far below the first quarter.
This is the main risk that could push the stock down and balances the positive earnings news.
Bonus share transfer and dividend registration Chengzhi registered a plan to transfer 4 bonus shares for every 10 held, the highest ratio among 15 companies that day. While this does not change the company's value, it often attracts short-term buying interest.
This corporate action can affect near-term demand for the shares and is a new event this period.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.